Page 42 - Ovarian Cancer Surgery - Quality Indicators

131. Aletti, G.D., Dowdy, S.C., Podratz, K.C.
& Cliby, W.A. Relationship among
surgical complexity, short-term morbidity,
and overall survival in primary surgery for
advanced ovarian cancer. Am J Obstet
Gynecol 197, 676 e671-677 2007.
132. Aletti, G.D., Dowdy, S.C., Podratz, K.C.
& Cliby, W.A. Surgical treatment of
diaphragm disease correlates with
improved survival in optimally debulked
advanced stage ovarian cancer. Gynecol
Oncol 100, 283-287 2006.
133. Aletti, G.D., Podratz, K.C., Jones, M.B. &
Cliby, W.A. Role of rectosigmoidectomy
and stripping of pelvic peritoneum in
outcomes of patients with advanced
ovarian cancer. J Am Coll Surg 203, 521-
526 2006.
134. Chan, J.K., et al. Stages III and IV
invasive epithelial ovarian carcinoma in
younger versus older women: what
prognostic factors are important? Obstet
Gynecol 102, 156-161 2003.
135. Chi, D.S., et al. Identification of
prognostic factors in advanced epithelial
ovarian carcinoma. Gynecol Oncol 82,
532-537 2001.
136. Chi, D.S., et al. What is the optimal goal
of primary cytoreductive surgery for bulky
stage IIIC epithelial ovarian carcinoma
EOC? Gynecol Oncol 103, 559-564
2006.
137. Eisenhauer, E.L., et al. The effect of
maximal surgical cytoreduction on
sensitivity to platinum-taxane
chemotherapy and subsequent survival in
patients with advanced ovarian cancer.
Gynecol Oncol 108, 276-281 2008.
138. Eisenkop, S.M., Friedman, R.L. & Wang,
H.J. Complete cytoreductive surgery is
feasible and maximizes survival in patients
with advanced epithelial ovarian cancer: a
prospective study. Gynecol Oncol 69, 103-
108 1998.
139. Eisenkop, S.M., et al. Relative influences
of tumor volume before surgery and the
cytoreductive outcome on survival for
 OVARIAN CANCER SURGERY - QUALITY INDICATORS 
42
patients with advanced ovarian cancer: a
prospective study. Gynecol Oncol 90, 390-
396 2003.
140. Hoskins, W.J., et al. The effect of diameter
of largest residual disease on survival after
primary cytoreductive surgery in patients
with suboptimal residual epithelial ovarian
carcinoma. Am J Obstet Gynecol 170, 974-
979; discussion 979-980 1994.
141. McGuire, W.P., et al. Assessment of dose-
intensive therapy in suboptimally debulked
ovarian cancer: a Gynecologic Oncology
Group study. J Clin Oncol 13, 1589-1599
1995.
142. Salani, R., Zahurak, M.L., Santillan, A.,
Giuntoli, R.L., 2nd & Bristow, R.E.
Survival impact of multiple bowel
resections in patients undergoing primary
cytoreductive surgery for advanced
ovarian cancer: a case-control study.
Gynecol Oncol 107, 495-499 2007.
143. van Geene, P., Varma, R., Dunn, J., Chan,
K.K. & Luesley, D.M. The prognostic
significance of intraperitoneal growth
characteristics in epithelial ovarian
carcinoma. Int J Gynecol Cancer 6, 219-
224 1996.
144. Armstrong, D.K., et al. Intraperitoneal
cisplatin and paclitaxel in ovarian cancer.
N Engl J Med 354, 34-43 2006.
145. Markman, M., et al. Phase III trial of
standard-dose intravenous cisplatin plus
paclitaxel versus moderately high-dose
carboplatin followed by intravenous
paclitaxel and intraperitoneal cisplatin in
small-volume stage III ovarian carcinoma:
an intergroup study of the Gynecologic
Oncology Group, Southwestern Oncology
Group, and Eastern Cooperative Oncology
Group. J Clin Oncol 19, 1001-1007
2001.
146. McGuire, W.P., et al. Cyclophosphamide
and cisplatin compared with paclitaxel and
cisplatin in patients with stage III and
stage IV ovarian cancer. N Engl J Med
334, 1-6 1996.